Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Teva Pharmaceuticals International GmbH has agreed to bid $125 million for BioXcel Therapeutics, Inc., including a $57.5 million cash payment and up to $67.5 million contingent on future outcomes. The deal, pending court approval, involves the acquisition of various assets, including the IGALMI drug, which is currently approved for inpatient use in schizophrenia and bipolar disorders.

Teva will assume certain liabilities and face risks if the FDA rejects the supplemental New Drug Application seeking at-home treatment for acute agitation. The company could potentially gain an outpatient market for IGALMI, but this hinges on FDA approval of an expanded label. Teva's strategic move depends on securing the assets at a reasonable cost and the success of the FDA's decision on the at-home label application.